{
    "root": "93063df6-c566-473c-9f30-64d6986b6699",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ARSENIC TRIOXIDE",
    "value": "20250320",
    "ingredients": [
        {
            "name": "ARSENIC TRIOXIDE",
            "code": "S7V92P67HO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01169"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        }
    ],
    "indications": {
        "text": "arsenic trioxide arsenical indicated induction remission consolidation patients apl refractory , relapsed , retinoid anthracycline chemotherapy , whose apl characterized presence ( 15 ; 17 ) translocation pml/rar-alpha gene expression . ( 1.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "relapsed refractory apl : induction : administer 0.15 mg/kg/day intravenously daily bone marrow remission . exceed 60 days . ( 2.2 ) consolidation : administer 0.15 mg/kg/day intravenously daily 25 doses period 5 weeks . ( 2.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "arsenic trioxide contraindicated patients hypersensitivity arsenic .",
    "indications_original": "Arsenic trioxide is an arsenical indicated for induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. ( 1.2 )",
    "contraindications_original": "Relapsed or refractory APL: Induction: Administer 0.15 mg/kg/day intravenously daily until bone marrow remission. Do not exceed 60 days. ( 2.2 ) Consolidation: Administer 0.15 mg/kg/day intravenously daily for 25 doses over a period of up to 5 weeks. ( 2.2 )",
    "adverseReactions_original": "Arsenic trioxide is contraindicated in patients with hypersensitivity to arsenic.",
    "drug": [
        {
            "name": "ARSENIC TRIOXIDE",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01169"
        }
    ]
}